Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07DTV
|
|||
| Former ID |
DCL000058
|
|||
| Drug Name |
AT7519
|
|||
| Synonyms |
LZE; AT 7519, AT7519; AT-7519; 4-[(2,6-dichlorobenzoyl)amino]-N-(4-piperidyl)-2H-pyrazole-3-carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Astex Therape.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H17Cl2N5O2
|
|||
| Canonical SMILES |
C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl
|
|||
| InChI |
1S/C16H17Cl2N5O2/c17-10-2-1-3-11(18)13(10)15(24)22-12-8-20-23-14(12)16(25)21-9-4-6-19-7-5-9/h1-3,8-9,19H,4-7H2,(H,20,23)(H,21,25)(H,22,24)
|
|||
| InChIKey |
OVPNQJVDAFNBDN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 844442-38-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16428822, 44379310, 50096508, 56269605, 74576064, 99437204, 99444613, 103643679, 124757315, 125164119, 135333280, 135685970, 135685971, 135685992, 135685993, 135727820, 136340234, 136367456, 136368084, 137041629, 137275934, 137275935, 141610040, 143499366, 144115640, 152234931, 152258863, 152344091, 160647712, 160969196, 162011646, 162202560, 162205110, 163642676, 163907975, 172918159, 174530768, 177748954, 178102290, 180371628, 185990438, 198975169, 223405959, 223704734, 224043268, 227215649, 242060190, 245357213, 245380549, 251910783
|
|||
| ChEBI ID |
CHEBI:91326
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02503709) Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery in National Cancer Institute (NCI). | |||
| REF 2 | Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther. 2009 Feb;8(2):324-32. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.